A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 793
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : NTCP
Long Form : normal tissue complication probability
No. Year Title Co-occurring Abbreviation
2022 Evaluation of plan robustness on the dosimetry of volumetric arc radiotherapy (VMAT) with set-up uncertainty in Nasopharyngeal carcinoma (NPC) radiotherapy. CBCT, NPC, TCP, TPS, U-plans, VMAT, VMAT
2022 Small spot size versus large spot size: Effect on plan quality for lung cancer in pencil beam scanning proton therapy. CTV, EUD, PBS, WCS
2021 A clinical trial to compare a 3D-printed bolus with a conventional bolus with the aim of reducing cardiopulmonary exposure in postmastectomy patients with volumetric modulated arc therapy. PMRT, VMAT
2021 A dosimetric and radiobiological evaluation of VMAT following mastectomy for patients with left-sided breast cancer. CN, CN, EAR, HI, IMRT, PMRT, PTV, SCCP, VMAT
2021 A novel semi auto-segmentation method for accurate dose and NTCP evaluation in adaptive head and neck radiotherapy. ART, DIR, DLC, HS, OARs, PCM, rCT, SAS
2021 A radiobiological comparison of hypo-fractionation versus conventional fractionation for breast cancer 3D-conformal radiation therapy. TCP
2021 A Risk Prediction Model by LASSO for Radiation-Induced Xerostomia in Patients With Nasopharyngeal Carcinoma Treated With Comprehensive Salivary Gland-Sparing Helical Tomotherapy Technique. AUC, LASSO, NPC
2021 A treatment planning study of urethra-sparing intensity-modulated proton therapy for localized prostate cancer. TCP, US-IMPT
2021 Assessment of the confidence interval in the multivariable normal tissue complication probability model for predicting radiation-induced liver disease in primary liver cancer. AUC, MLD, RILD
10  2021 Automated Non-Coplanar VMAT for Dose Escalation in Recurrent Head and Neck Cancer Patients. GTV, OAR, PTV, rHNC, SBRT, TCP, VMAT
11  2021 Biophysical Analysis of Acute and Late Toxicity of Radiotherapy in Gastric Marginal Zone Lymphoma-Impact of Radiation Dose and Planning Target Volume. LKB, OAR, PTV
12  2021 Clinical suitability of deep learning based synthetic CTs for adaptive proton therapy of lung cancer. APT, CBCT, DCNN, MAE, ME, pCTs, rCT
13  2021 Comparison of a Hybrid IMRT/VMAT technique with non-coplanar VMAT and non-coplanar IMRT for unresectable olfactory neuroblastoma using the RayStation treatment planning system-EUD, NTCP and planning study. C/L, CN, CTV, EUD, HI, I/L, IMRT, MUs, nc, OARs, ONB, PTV
14  2021 Comparisons of normal tissue complication probability models derived from planned and delivered dose for head and neck cancer patients. EUD, HNC, OAR
15  2021 Degree of reduction in normal liver complication probability from free-breathing to breath-hold liver SBRT: a dose-escalation strategy using radiation dose-volume effect. BH, CC, CT, FB, ITV, MLD, NLV, OAR's, SBRT, SI
16  2021 Delivered dose-effect analysis of radiation induced rib fractures after thoracic SBRT. Aw, NSCLC, SBRT
17  2021 Development and validation of a normal tissue complication probability model for acquired nasal cavity stenosis and atresia after radical radiotherapy for nasopharyngeal carcinoma. ANCSA, NPC, ROC
18  2021 Dosimetric comparison and biological evaluation of fixed-jaw intensity-modulated radiation therapy for T-shaped esophageal cancer. FJ, IMRT, JT, MUs, SJ, TCP, VMAT
19  2021 Dosimetric comparison between carbon, proton and photon radiation for renal retroperitoneal soft tissue sarcoma recurrence or metastasis after radical nephrectomy. LKB, OARs, PTV-1, PTV-2, RRSTSRM
20  2021 Dosimetric Comparison, Treatment Efficiency Estimation, and Biological Evaluation of Popular Stereotactic Radiosurgery Options in Treating Single Small Brain Metastasis. CI, Cone-VMAT, GI, GK, GTV, HI, MLC-CRT, OARs, PTV, SRS, TCP
21  2021 Dosimetric predictors and Lyman normal tissue complication probability model of hematological toxicity in cervical cancer patients with treated with pelvic irradiation. CCRT, ff-IMRT, HT, LKB-NTCP, PBM, PTV, RTOG, TOMO
22  2021 Effective Organs-at-Risk Dose Sparing in Volumetric Modulated Arc Therapy Using a Half-Beam Technique in Whole Pelvic Irradiation. FF, HF, MLC, OAR, VMAT, VMAT-FF, WPRT
23  2021 Evaluation of target autocrop function in nasopharyngeal carcinoma SIB IMRT plan. CI, HI, IMRT, MUs, NPC, QA, SIB, TCP
24  2021 Exploratory Investigation of Dose-Linear Energy Transfer (LET) Volume Histogram (DLVH) for Adverse Events Study in Intensity Modulated Proton Therapy (IMPT). DLVC1, DLVCs, DVLC2, IMPT, LET, LET, SVM
25  2021 Functional avoidance-based intensity modulated proton therapy with 4DCT derived ventilation imaging for lung cancer. CTV, IMPT, OAR, VMAT
26  2021 How can scanned proton beam treatment planning for low-grade glioma cope with increased distal RBE and locally increased radiosensitivity for late MR-detected brain lesions? CEBLs, LGG, TP
27  2021 Identification of patient benefit from proton beam therapy in brain tumour patients based on dosimetric and NTCP analyses. PBT
28  2021 Impact of daily plan adaptation on organ-at-risk normal tissue complication probability for adrenal lesions undergoing stereotactic ablative radiation therapy. MR, OARs, SABR
29  2021 Impact of RBE variations on risk estimates of temporal lobe necrosis in patients treated with intensity-modulated proton therapy for head and neck cancer. HNC, RBE, TLIC, TLN
30  2021 Impact of respiratory motion in dosimetric and clinical advantages for adjuvant left-sided breast radiotherapy. BCS, DIBH, IE, LAD, LV, ME
31  2021 Independent external validation using the EORTC HNCG-ROG 1219 DAHANCA trial data of NTCP models for acute oral mucositis. AUC-ROC, g3OM, HNC, HNSCC
32  2021 Individualized Fraction Regimen of SBRT Patients With Non-Small Cell Lung Cancer Based on Uncomplicated and Cancer-Free Control Probability. IFR, NSCLC, SBRT, SCP, TCP, UCFCP
33  2021 Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference. mpMRI, PCa, RT, TCP
34  2021 Inter-Observer Variation in Delineating the Pharyngeal Constrictor Muscle as Organ at Risk in Radiotherapy for Head and Neck Cancer. CIs, Do-IMRT, GS, IOV, IPCM, PCM, RTQA, SMPCM
35  2021 Investigate the Dosimetric and Potential Clinical Benefits Utilizing Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost Technique for Locally Advanced Pancreatic Cancer: A Comparison Between Photon and Proton Beam Therapy. DVH, HI, IMPT, LAPC, RMSD, RVH, SBRT, SIB, VMAT
36  2021 Investigating the potential of proton therapy for hypoxia-targeted dose escalation in non-small cell lung cancer. NSCLC, OER, VMAT
37  2021 Isotoxic investigation of 18F-FDG PET/CT-guided dose escalation with intensity-modulated radiotherapy for LA-NSCLC. MLD, TCP
38  2021 Local tumor control and treatment related toxicity after plaque brachytherapy for uveal melanoma: A systematic review and a data pooled analysis. EPB, LTC, TCP, TPS, UM
39  2021 Lung Stereotactic Body Radiotherapy (SBRT) Using Spot-Scanning Proton Arc (SPArc) Therapy: A Feasibility Study. IMPT, IMPTvolumetric, ITV, RBE, SBRT, SPArc
40  2021 Mean heart dose-based normal tissue complication probability model for pericardial effusion: a study in oesophageal cancer patients. AUC, LKB, MHD, PCE, ROC, S-PCE
41  2021 Modelling of late side-effects following cranial proton beam therapy. AUC, PBT
42  2021 Multivariate NTCP Model of Hypothyroidism After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma. IMRT
43  2021 Neurocognitive Effects and Necrosis in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review. CNS, IQ, MTX, RT
44  2021 Normal tissue complication probability (NTCP) models for predicting temporal lobe injury after intensity-modulated radiotherapy in nasopharyngeal carcinoma: A large registry-based retrospective study from China. AUC, CI, IMRT, IQR, NPC, TLI
45  2021 Normal Tissue Complication Probability (NTCP) Prediction Model for Osteoradionecrosis of the Mandible in Patients With Head and Neck Cancer After Radiation Therapy: Large-Scale Observational Cohort. AUC, HNC, ORN, ORN, RT
46  2021 Normal tissue complication probability modeling to guide individual treatment planning in pediatric cranial proton and photon radiotherapy. IMPT, IMRT, PT
47  2021 Normal tissue complication probability models for prospectively scored late rectal and urinary morbidity after proton therapy of prostate cancer. GR2A, GR2B, LKB, PT
48  2021 NTCP modeling and dose-volume correlations for acute xerostomia and dry eye after whole brain radiation. LKB, RS, WBRT
49  2021 Online adaptive radiotherapy potentially reduces toxicity for high-risk prostate cancer treatment. MRgART
50  2021 Optimal Allocation of Proton Therapy Slots in Combined Proton-Photon Radiation Therapy. ---
51  2021 Optimizing oropharyngeal cancer management by using proton beam therapy: trends of cost-effectiveness. ICER, IMPT, IMRT, OPC, PBT, QALY, WTP
52  2021 Photon beam energy dependent single-arc volumetric modulated arc optimization. DVHs, EUD
53  2021 Potential Morbidity Reduction for Lung Stereotactic Body Radiation Therapy Using Respiratory Gating. GW, SBRT
54  2021 Prediction of Radiation-Induced Hypothyroidism Using Radiomic Data Analysis Does Not Show Superiority over Standard Normal Tissue Complication Models. IMRT, RIHT
55  2021 Proton range uncertainty reduction benefits for skull base tumors in terms of normal tissue complication probability (NTCP) and healthy tissue doses. ---
56  2021 Proton vs. photon radiotherapy for MR-guided dose escalation of intraprostatic lesions. EqD2, IL
57  2021 Pulmonary Toxicity after Total Body Irradiation-An Underrated Complication? Estimation of Risk via Normal Tissue Complication Probability Calculations and Correlation with Clinical Data. TBI
58  2021 Quality of life and toxicity guided treatment plan optimisation for head and neck cancer. HNC, OAR, QoL
59  2021 Radiomics Analysis of 3D Dose Distributions to Predict Toxicity of Radiotherapy for Cervical Cancer. AUC, DVH, GU, LACC
60  2021 Radiotherapeutic treatment options for oligotopic malignant liver lesions. HDR, TCP, VMAT
61  2021 Spatial descriptions of radiotherapy dose: normal tissue complication models and statistical associations. ---
62  2021 Stereotactic body radiotherapy for apical lung tumors: Dosimetric analysis of the brachial plexus and preliminary clinical outcomes. AUC, BP, BPI, RTOG, SBRT
63  2021 Study on the Appropriate Timing of Postoperative Adaptive Radiotherapy for High-Grade Glioma. ART, CI, OARs, PTV, TCP
64  2021 The Dosimetric Outcome of a Rotational Planning Target Volume in Patients With Oropharyngeal Cancers. CTV, PCM, PTV
65  2021 The feasibility of a dose painting procedure to treat prostate cancer based on mpMR images and hierarchical clustering. ADC, DILs, DP, mpMR, OARs, PSA, PTVs, SIB-IMRT, TCP
66  2021 The Hippocampus: A New Organ at Risk for Postoperative Radiation Therapy for Bucco-alveolar Cancer? A Dosimetric and Biological Analysis. Dmax, Dmin, EUD, PORT
67  2021 The impact of nutritional counseling on thyroid disorders in head and neck cancer patients after (chemo)radiotherapy: results from aprospective interventional trial. TSH
68  2021 Toward MR-integrated proton therapy: modeling the potential benefits for liver tumors. CBCT, MRI, PTV
69  2021 Ultra hypofractionated extended nodal irradiation using volumetric modulated arc therapy for oligorecurrent pelvic nodal prostate cancer. BED, ENI, GTVn, OARs, PCa, PTVn, SABR, SIB, TCP, VMAT
70  2021 Y-90 SIRT: evaluation of TCP variation across dosimetric models. SIRT, TCP
71  2020 3D image-guided treatment planning for Ruthenium-106 brachytherapy of choroidal melanomas. Ru-106, TCP
72  2020 A DNA damage multiscale model for NTCP in proton and hadron therapy. ---
73  2020 A Nordic-Baltic perspective on indications for proton therapy with strategies for identification of proper patients. ---
74  2020 A planning study of focal dose escalations to multiparametric MRI-defined dominant intraprostatic lesions in prostate proton radiation therapy. DILs, IMPT, mpMRI, OAR, PBS, SIB, TCP
75  2020 Adaptive time management for patients who have non-small cell lung cancer and underwent definitive radiotherapy: a dosimetric study of different gap duration scenarios. ATM, DVH, NSCLC, TCP
76  2020 Application of Radiomics for the Prediction of Radiation-Induced Toxicity in the IMRT Era: Current State-of-the-Art. IMRT, QUANTEC
77  2020 Beam angle comparison for distal esophageal carcinoma patients treated with intensity-modulated proton therapy. DVH, IMPT
78  2020 Brainstem NTCP and Dose Constraints for Carbon Ion RT-Application and Translation From Japanese to European RBE-Weighted Dose. CIRT, CNAO, D MKM, LEM I, MKM, NIRS, RBE
79  2020 Comparison of conventional and advanced radiotherapy techniques for left-sided breast cancer after breast conserving surgery. FIF, IMRT, LAR, MA-VMAT, NC-VMAT, RCE, STD-VMAT, WBRT
80  2020 Comparison of the suitability of CBCT- and MR-based synthetic CTs for daily adaptive proton therapy in head and neck patients. CBCT, DSC, MAE, ME, MR, OARs, pCTs, PT, sCT
81  2020 Comprehensive Comparison of Progressive Optimization Algorithm Based Automatic Plan and Manually Planned Treatment Technique for Cervical-Thoracic Esophageal Cancers. 7f-IMRT, CI, CTEC, HI, IMRT, POA-VMAT
82  2020 Cone-Beam-CT Guided Adaptive Radiotherapy for Locally Advanced Non-small Cell Lung Cancer Enables Quality Assurance and Superior Sparing of Healthy Lung. ART, CBCT, dPlan, gEUD, GTV, IMRT, NSCLC, OAR
83  2020 Correlation of clinical outcome, radiobiological modeling of tumor control, normal tissue complication probability in lung cancer patients treated with SBRT using Monte Carlo calculation algorithm. s-BED, SBRT, TCP, XVMC
84  2020 Dose-Response and Normal Tissue Complication Probabilities after Proton Therapy for Choroidal Melanoma. DVHs, LASSO, PT, VA
85  2020 Dose-Volume and Radiobiological Model-Based Comparative Evaluation of the Gastrointestinal Toxicity Risk of Photon and Proton Irradiation Plans in Localized Pancreatic Cancer Without Distant Metastasis. 3D-PSPBT, ANOVA, CTV, GI, IMRT, LKB, OAR, PTV, VMAT
86  2020 Dosimetric Analysis and Normal-Tissue Complication Probability Modeling of Child-Pugh Score and Albumin-Bilirubin Grade Increase After Hepatic Irradiation. ALBI, CP, LKB, RT
87  2020 Dosimetric and Radiobiological Comparison of Five Techniques for Postmastectomy Radiotherapy with Simultaneous Integrated Boost. b-HT, ff-IMRT, hy-IMRT, OARs, PMRT, SCCP, SIB, TD, unb-HT
88  2020 Dosimetric evaluation of phantoms including metal objects with high atomic number for use in intensity modulated radiation therapy. GPRs, IMRT, OARs, QA
89  2020 Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts. CT, DIL-SIB, GTV, PET, PSMA, TCP
90  2020 Effects From Nonuniform Dose Distribution in the Spinal Nerves of Pigs: Analysis of Normal Tissue Complication Probability Models. ---
91  2020 Evaluating different radiotherapy treatment plans, in terms of critical organ scoring index, conformity index, tumor control probability, and normal tissue complication probability calculations in early glottic larynx carcinoma. CI, COSI, DVH, IMRT, NT, OARs, OLAFs, PTV, TCP
92  2020 Evaluation of Dose Distribution and Normal Tissue Complication Probability of a Combined Dose of Cone-Beam Computed Tomography Imaging with Treatment in Prostate Intensity-Modulated Radiation Therapy. CBCT, IMRT
93  2020 Evaluation of dose distribution differences from five algorithms implemented in three commercial treatment planning systems for lung SBRT. PTV, SBRT, VMAT
94  2020 Evaluation of plan quality and robustness of IMPT and helical IMRT for cervical cancer. CTV, DVHBW, IMPT, IMRT, LKB, OARs, PS, SRO, TRO
95  2020 Evaluation of small bowel motion and feasibility of using the peritoneal space to replace bowel loops for dose constraints during intensity-modulated radiotherapy for rectal cancer. BL, IMRT, PS
96  2020 Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes. HNC, PSQA, TCP, TPS
97  2020 First experience with model-based selection of head and neck cancer patients for proton therapy. HNC, IMPT, MBS, OARs
98  2020 First-passage times and normal tissue complication probabilities in the limit of large populations. ---
99  2020 Generalizability assessment of head and neck cancer NTCP models based on the TRIPOD criteria. HNC
100  2020 Impact of radiation techniques on lung toxicity in patients with mediastinal Hodgkin's lymphoma. IFRT, IMRT, RT